Edwards Lifesciences (NYSE:EW) had its price objective hoisted by stock analysts at Jefferies Financial Group from $168.00 to $180.00 in a research report issued on Thursday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Jefferies Financial Group’s price objective suggests a potential upside of 14.50% from the stock’s current price. Jefferies Financial Group also issued estimates for Edwards Lifesciences’ Q1 2019 earnings at $1.35 EPS, Q2 2019 earnings at $1.33 EPS, Q4 2019 earnings at $1.29 EPS, FY2019 earnings at $5.22 EPS, FY2020 earnings at $5.86 EPS, FY2021 earnings at $6.57 EPS and FY2022 earnings at $7.42 EPS.
Several other research analysts have also recently commented on the company. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Wednesday, September 26th. Bank of America cut Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Guggenheim cut Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Northland Securities reiterated a “hold” rating and issued a $120.00 price target on shares of Edwards Lifesciences in a research note on Thursday, October 11th. Finally, SunTrust Banks boosted their price target on Edwards Lifesciences to $200.00 and gave the stock a “buy” rating in a research note on Friday, September 28th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $162.85.
Shares of EW opened at $157.21 on Thursday. The stock has a market cap of $34.14 billion, a price-to-earnings ratio of 41.37, a P/E/G ratio of 2.15 and a beta of 0.90. Edwards Lifesciences has a 12 month low of $110.68 and a 12 month high of $175.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.31.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The business had revenue of $906.60 million for the quarter, compared to analysts’ expectations of $927.56 million. During the same quarter in the previous year, the firm posted $0.84 earnings per share. The company’s revenue was up 10.4% compared to the same quarter last year. As a group, equities research analysts predict that Edwards Lifesciences will post 4.7 earnings per share for the current fiscal year.
In related news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $144.02, for a total value of $4,738,258.00. Following the completion of the sale, the chief executive officer now directly owns 76,026 shares of the company’s stock, valued at $10,949,264.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Catherine M. Szyman sold 700 shares of the business’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $142.64, for a total value of $99,848.00. Following the completion of the sale, the vice president now directly owns 27,772 shares of the company’s stock, valued at $3,961,398.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 187,156 shares of company stock valued at $27,603,513. 1.84% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in EW. Honkamp Krueger Financial Services Inc. bought a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $106,000. SRS Capital Advisors Inc. grew its holdings in shares of Edwards Lifesciences by 317.5% during the third quarter. SRS Capital Advisors Inc. now owns 668 shares of the medical research company’s stock valued at $116,000 after purchasing an additional 508 shares during the last quarter. TLP Group LLC grew its holdings in shares of Edwards Lifesciences by 163.6% during the third quarter. TLP Group LLC now owns 680 shares of the medical research company’s stock valued at $118,000 after purchasing an additional 422 shares during the last quarter. LFA Lugano Financial Advisors SA bought a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $121,000. Finally, Prime Capital Investment Advisors LLC grew its holdings in shares of Edwards Lifesciences by 577.9% during the third quarter. Prime Capital Investment Advisors LLC now owns 705 shares of the medical research company’s stock valued at $123,000 after purchasing an additional 601 shares during the last quarter. 82.55% of the stock is owned by hedge funds and other institutional investors.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Featured Article: Analyst Ratings
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.